Spots Global Cancer Trial Database for A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Official Title: Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours
Study ID: NCT02788578
Conditions
Interventions
Study Description
Brief Summary: The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or in the digestive system as there is currently limited data on these treatments used together for these types of neuroendocrine tumours.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peter MacCallum Cancer Centre, East Melbourne, , Australia
IUCT Oncopole, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Zentralklinil Bad Berka, Bad Berka, , Germany
Charité, Berlin, , Germany
Klinikum rechts der Usar, München, , Germany
Unversità degli Studi di Messina, Messina, , Italy
IEO Institutio Europeo di Oncologia, Milano, , Italy
Queen Elizabeth Hospital Birmingham, Birmingham, , United Kingdom
Kings College Hospital, London, , United Kingdom
Royal Free Hospital London, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Contact Details
Name: Ipsen Medical Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
